AdAlta (1AD) 2021年年度报告「ASX」.pdf

1、ANNUAL REPORTFOR THE YEAR ENDED 30 JUNE 2021ADALTA LTDABN 92 120 332 925CORPORATE DIRECTORY 3CHAIRS LETTER 5CEO AND MANAGING DIRECTORS LETTER 6DIRECTORS REPORT 7AUDITORS INDEPENDENCE DECLARATION 27STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME 28STATEMENT OF FINANCIAL POSITION 29STATEMEN

2、T OF CHANGES IN EQUITY 30STATEMENT OF CASH FLOWS 31NOTES TO THE FINANCIAL STATEMENTS 32DIRECTORS DECLARATION 48INDEPENDENT AUDITORS REPORT TO THE MEMBERS OF ADALTA LIMITED 49SHAREHOLDER INFORMATION 54CONTENTS AdAlta Limited Annual Report 2021 ABN 92 120 332 9252DIRECTORSDr Paul MacLemanDr Timothy Ol

3、dhamMs Elizabeth McCallDr Robert PeachDr David Fuller(appointed 22 July 2020)Dr James Williams(alternate to Elizabeth McCall)COMPANY SECRETARYMr Cameron JonesREGISTERED OFFICEUnit 15/2 Park DriveBundoora Vic 3083AUDITORButler Settineri(Audit)Pty LtdUnit 16,First Floor,100 Railway RoadSubiaco,Western

4、 Australia 6008SHARE REGISTRYAutomic Registry ServicesLevel 5126 Phillip StreetSydney,NSW 2000Tel:1300 288 664STOCK EXCHANGE LISTINGAdalta Limited shares are listed on the Australian Securities Exchange.ASX CODE1ADWEBSITE.auCORPORATE DIRECTORYAdAlta Limited Annual Report 2021 ABN 92 120 332 9253AdAl

5、ta Limited Annual Report 2021 ABN 92 120 332 9254In FY2021 we have continued to make substantial progress in progressing our i-body enabled assets and expanding our pipeline.Our lead asset,AD-214,has now successfully completed a Phase I clinical trial,demonstrating an excellent safety profile in sin

6、gle and multiple intravenous doses in healthy volunteers.We also successfully developed a radio-labelled version of AD-214 for PET imaging,with pre-clinical studies demonstrating the value of this asset as a translational research tool.We now have a clear pathway to clinical trials in Idiopathic Pul